Monitor for BLA submission timing in 2027 and any FDA breakthrough/fast track designations. Watch for upcoming medical meeting presentations and potential partnership or commercialization updates. The sustained efficacy through 24 weeks and differentiation in omalizumab-refractory patients are key competitive advantages.
Price Chart
Executive Summary
Celldex reported positive Phase 3 topline results for barzolvolimab in chronic spontaneous urticaria (CSU). Both EMBARQ-CSU1 and EMBARQ-CSU2 trials met the primary endpoint (mean change in UAS7 at Week 12) and all key secondary endpoints with high statistical significance, including in omalizumab-refractory patients. A BLA submission is planned for 2027, positioning barzolvolimab as a potential transformational therapy in CSU.
Key Facts
- Both Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials met the primary endpoint (mean change from baseline in UAS7 at Week 12) with p<.00001 for both doses vs placebo.
- All key secondary endpoints were met with high statistical significance.
- Complete Response (UAS7=0) at Week 12: 42-46% for barzolvolimab doses vs 9-13% for placebo.
- In omalizumab-refractory patients, Complete Response at Week 12: 42-55% for barzolvolimab vs 9-15% for placebo.
- Efficacy sustained or deepened from weeks 12 to 24.
- Favorable safety profile consistent with prior Phase 2 experience.
- BLA submission planned for 2027.
- 1,939 patients randomized across both trials.
Financial Impact
Positive Phase 3 data in a large unmet need market (CSU) positions barzolvolimab for potential blockbuster status; no financial figures provided in the release.
Risk Factors
- BLA submission and FDA approval are not guaranteed; regulatory risks remain.
- Competition from existing CSU therapies (omalizumab, ligelizumab) and pipeline candidates.
- Commercial execution risk as Celldex transitions to a commercial-stage organization.
- Manufacturing and supply chain risks for a biologic product.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3366115 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 20d ago | SC 13G/A | $30.43 | awaiting T+60 | — | $30.15 (−0.92%) |
Sep 22, 2026 5w ago | Institutional Cluster | $33.51 | awaiting T+60 | — | $30.15 (−10.03%) |
Sep 22, 2026 5w ago | 8-K | $33.51 | awaiting T+60 | — | $30.15 (−10.03%) |
Sep 22, 2026 5w ago | Press Release | $33.51 | awaiting T+60 | — | $30.15 (−10.03%) |
Jun 14, 2026 19w ago | Press Release | $32.12 $38.10 | ▼ −18.62% | ▼ −18.22% | $30.15 (+6.13%) |
Jun 14, 2026 19w ago | Press Release | $32.12 $38.10 | ▲ +18.62% | ▲ +18.22% | $30.15 (−6.13%) |
Jun 11, 2026 19w ago | Institutional Cluster | $29.96 $39.12 | ▲ +30.57% | ▲ +26.75% | $30.15 (+0.63%) |
Jun 10, 2026 19w ago | Press Release | $29.96 $39.12 | ▲ +30.57% | ▲ +26.75% | $30.15 (+0.63%) |
May 7, 2026 24w ago | 8-K | $33.97 $39.05 | ▲ +14.95% | ▲ +10.11% | $30.15 (−11.25%) |
May 7, 2026 24w ago | Press Release | $33.97 $39.05 | ▲ +14.95% | ▲ +10.11% | $30.15 (−11.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers